Victor Ambros has joined the molecular medicine faculty at the University of Massachusetts Medical School.
Ambros, a pioneer in the field of microRNAs, comes to UMMS from Dartmouth Medical School where he served most recently as a professor of genetics. He will officially begin at UMMS in January.
Ambros received his undergraduate and graduate degrees at the Massachusetts Institute of Technology, where he also carried out his postdoctoral studies. Before Dartmouth, he was a faculty member at Harvard University.
Quark Pharmaceuticals has named Joseph Marr as its chief medical officer.
Marr previously served as president of BioMed, a consulting firm. At the same time, he was also a general partner at venture capital company Pacific Rim Ventures. He was also formerly vice president of research and development at Ribozyme Pharmaceuticals, which later became Sirna Therapeutics.
He holds an MD from the Johns Hopkins University School of Medicine.
RXi Pharmaceuticals, the RNAi subsidiary of CytRx, has named Stephen DiPalma as its CFO.
DiPalma replaces James Warren, who RXi said has left the company to pursue other opportunities.
DiPalma was most recently co-founder, president, and CEO of Catalyst Oncology, which recently merged with another firm. Before this, he served as CFO of Milkhaus Laboratory.
He holds an MBA from BabsonCollege and a BS in business administration from the University of Massachusetts at Lowell.